HistoSonics Announces FDA Approval of its Pivotal IDE #HOPE4KIDNEY Trial
- Written by PR Newswire
Company to Utilize its New Edison™ System with Advanced Imaging Features for Use in Kidney Tumors
MINNEAPOLIS, Feb. 13, 2023 /PRNewswire/ -- HistoSonics, (www.histosonics.com), the developer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today the US Food and Drug Administration (FDA) has...
Read more: HistoSonics Announces FDA Approval of its Pivotal IDE #HOPE4KIDNEY Trial